Here are the 10-Q quarterly reports from Celularity Inc. (CELU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CELU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELU filings page.
Celularity Inc. (CELU) reported second-quarter 2026 revenue of $5.432 million, versus $5.736 million a year earlier, and net income of $706,000 versus a $24.524 million loss. For the six months ended June 30, 2026, revenue was $9.278 million versus $17.162 million, and net income was $1.580 million versus a $44.278 million loss. Second-quarter results included a $6.730 million gain on the Sequence settlement.
At June 30, cash and cash equivalents were $586,000 and the working-capital deficit was $53.290 million. Management said substantial doubt existed about Celularity’s ability to continue as a going concern and that existing cash was insufficient to fund operations, meet payroll and satisfy contractual debt obligations for the 12 months following issuance. Six-month operating cash flow was $339,000, including $12.159 million in proceeds from the sale of New Jersey net operating loss carryforwards; excluding those proceeds, operating activities used net cash.
On September 24, 2026, a private-placement closing generated $8.8 million in net cash proceeds within a recapitalization plan contemplating up to $25.0 million in new cash investment. Celularity also sold NexGel an exclusive license for $13.3 million, with potential milestone payments of up to $20.0 million. The transaction provides for restructuring approximately $3.0 million of existing debt; the original note’s maturity was extended from December 31, 2026, to December 31, 2028.
Celularity Inc. (CELU) reported first-quarter 2026 revenue of $3.846 million, compared with $11.426 million a year earlier, as product sales were $866,000 versus $9.018 million. Net income was $874,000, versus a $19.754 million net loss; the quarter included $12.159 million from selling New Jersey net operating loss carryforwards. Operating cash flow was $1.447 million, but excluding those proceeds, operations used net cash. Cash and cash equivalents were $368,000 at March 31, 2026.
Management cited substantial doubt about Celularity’s ability to continue as a going concern within one year after issuance, saying cash on hand was insufficient for operations, payroll and debt obligations over the next 12 months and additional financing was needed. The NexGel agreement initially described $35 million in aggregate consideration, including up to $20.0 million in milestones; its April-amended terms describe $13.3 million in consideration, including $4.8 million cash at closing, $0.6 million Q2 cash contingent on filing the 2025 annual report, $2.9 million in assumed employee commissions and a $5.0 million, 18-month convertible note. Nasdaq notices cited market value below $35 million and a bid below $1.00, with deadlines of December 7, 2026, for market value and January 19, 2027, for bid price.
Celularity Inc. filed its quarterly report for the period ended September 30, 2025, highlighting lower revenue and ongoing liquidity pressure. Total net revenues were $5,284 for the quarter, and the company reported a net loss of $23,076. For the nine months, net revenues reached $22,446 with a net loss of $67,354.
The company disclosed substantial doubt about its ability to continue as a going concern, citing continued operating losses and the need for additional financing. As of September 30, 2025, cash and cash equivalents were $120 and restricted cash was $10,135. Stockholders’ (deficit) equity was $(20,094), reflecting accumulated losses and new obligations, including a long-term licensing obligation of $34,234. Product sales fell year over year while services were steady and license/royalty revenue declined.
Shares outstanding were 28,216,485 as of September 30, 2025, and 28,328,880 as of November 14, 2025.